Synthesis and in vitro Metabolic Stability of Sterically Shielded Antimycobacterial Phenylalanine Amides

Author:

Lang Markus1,Ganapathy Uday S.2,Mann Lea1,Seidel Rüdiger W.1ORCID,Goddard Richard3ORCID,Erdmann Frank1,Dick Thomas245ORCID,Richter Adrian1ORCID

Affiliation:

1. Institut für Pharmazie Martin-Luther-Universität Halle-Wittenberg Wolfgang-Langenbeck-Str. 4 06120 Halle (Saale) Germany

2. Center for Discovery and Innovation Hackensack Meridian Health 111 Ideation Way 07110 Nutley New Jersey USA

3. Max-Planck-Institut für Kohlenforschung Kaiser-Wilhelm-Platz 1 45470 Mülheim an der Ruhr Germany

4. Department of Medical Sciences Hackensack Meridian School of Medicine 123 Metro Blvd 07110 Nutley New Jersey USA

5. Department of Microbiology and Immunology Georgetown University 3900 Reservoir Road, N.W. 20007 Washington DC USA

Abstract

AbstractNα‐aroyl‐N‐aryl‐phenylalanine amides (AAPs) are RNA polymerase inhibitors with activity against Mycobacterium tuberculosis and non‐tuberculous mycobacteria. We observed that AAPs rapidly degrade in microsomal suspensions, suggesting that avoiding hepatic metabolism is critical for their effectiveness in vivo. As both amide bonds are potential metabolic weak points of the molecule, we synthesized 16 novel AAP analogs in which the amide bonds are shielded by methyl or fluoro substituents in close proximity. Some derivatives show improved microsomal stability, while being plasma‐stable and non‐cytotoxic. In parallel with the metabolic stability studies, the antimycobacterial activity of the AAPs against Mycobacterium tuberculosis, Mycobacterium abscessus, Mycobacterium avium and Mycobacterium intracellulare was determined. The stability data are discussed in relation to the antimycobacterial activity of the panel of compounds and reveal that the concept of steric shielding of the anilide groups by a fluoro substituent has the potential to improve the stability and bioavailability of AAPs.

Publisher

Wiley

Reference70 articles.

1. World Health Organization “Global Tuberculosis Report 2023 ” can be found underhttps://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023 2023.

2.  

3. Rifampicin Mono-Resistant Tuberculosis—A Review of an Uncommon But Growing Challenge for Global Tuberculosis Control

4. Multi-Drug Resistant and Extensively-Drug Resistant Tuberculosis

5. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3